Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND MEMBER OF COMPETITION EXECUTIVE COMMITTEE AND

APPOINTMENT OF ACTING CHIEF EXECUTIVE OFFICER

RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND MEMBER OF COMPETITION EXECUTIVE COMMITTEE

The board (the "Board") of directors (the "Director(s)") of Beijing Tong Ren Tang Chinese Medicine Company Limited (the "Company") hereby announces that Mr. Yu Jin ("Mr. Yu") has resigned as an executive Director, the chief executive officer and member of the competition executive committee of the Company with effect from 28 March 2024, due to personal endeavors.

Mr. Yu has confirmed that he has no disagreement with the Board or the Company and there is no matter in relation to his resignation that needs to be brought to the attention of shareholders of the Company or The Stock Exchange of Hong Kong Limited.

During his tenure of service at the Company, Mr. Yu faithfully performed his duties and contributed to the Company's development. The Board would like to take this opportunity to express its sincere gratitude to Mr. Yu for his invaluable contribution.

APPOINTMENT OF ACTING CHIEF EXECUTIVE OFFICER

The Board would like to further announce that Mr. Chen Fei ("Mr. Chen"), in addition to being an executive Director and the executive deputy general manager of the Company, has been appointed as the acting chief executive officer of the Company with effect from 28 March 2024.

The biographical details of Mr. Chen are as follows:

Chen Fei, aged 53, is an executive Director and the executive deputy general manager of the Company and a director of various subsidiaries of the Company. Mr. Chen was appointed as a non-executive Director of the Company on 24 March 2020 and was re-designated as an executive Director and was appointed as the chief executive officer of the Company on 11 March 2021, and then was re-designated as the executive deputy general manager of the Company on 19 April 2023. Mr. Chen joined Beijing Tong Ren Tang Group in August 1994 and formerly served as the manager and deputy manager of Operational Management Department of Tong Ren Tang Holdings, the deputy manager of Pricing Department of Tong Ren Tang Holdings, the deputy manager of Economic Operation Department of Tong Ren Tang Holdings and the general manager of Beijing Tong Ren Tang (Thailand) Co., Ltd.. Mr. Chen obtained a bachelor's degree in Chinese medicine from School of Chinese Medicine of Beijing Union University in August 1994.

A service contract (the "Contract") was entered into between the Company and Mr. Chen on 11 March 2024 for a period of three years. Pursuant to the Contract, Mr. Chen will not receive any director's fee as an executive Director. For the year ended 31 December 2023, Mr. Chen was entitled to a total emolument of approximately HK\$975,000 comprising salaries and other benefits and retirement benefit scheme contributions. Such remuneration, including the discretionary bonus, are determined by reference to his work performance, duties and responsibilities with the Company, the prevailing market rate and the remuneration policy of the Company, and are not covered by the Contract.

As at the date of this announcement, Mr. Chen was interested in 43,000 shares of the Company, representing approximately 0.005% of the total number of shares of the Company in issue.

As at the date of this announcement, save as disclosed above, Mr. Chen has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Save as disclosed above, Mr. Chen does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Listing Rules")) of the Company nor does he hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Mr. Chen has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the shareholders of the Company in connection with the aforesaid appointment.

By order of the Board Beijing Tong Ren Tang Chinese Medicine Company Limited Gu Hai Ou

Chairman

Hong Kong, 28 March 2024

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors: Independent Non-executive Directors:

Mr. Gu Hai Ou (*Chairman*) Mr. Tsang Yok Sing, Jasper

Mr. Chen Fei

Mr. Xu Hong Xi

Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li